{"id":"dapagliflozin-acei-treatment","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"5-10","effect":"Urinary tract infections"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-10","effect":"Cough (ACE inhibitor-related)"},{"rate":"2-5","effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion independent of insulin, thereby lowering blood glucose levels. The ACE inhibitor component blocks the renin-angiotensin-aldosterone system, reducing blood pressure and providing renal protection. This combination targets both glycemic control and cardiovascular/renal outcomes in diabetes management.","oneSentence":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to reduce blood glucose, while an ACE inhibitor blocks angiotensin-converting enzyme to lower blood pressure and reduce proteinuria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:01.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus with hypertension or chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT07303556","phase":"NA","title":"Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazarbayev University","startDate":"2024-12-18","conditions":"Heart Failure, Diabete Type 2, Arterial Hypertension","enrollment":120},{"nctId":"NCT07356388","phase":"PHASE3","title":"FINEPKT - Finerenone in Proteinuria Patients After Kidney Transplan","status":"ACTIVE_NOT_RECRUITING","sponsor":"kewen Chen,MD","startDate":"2025-01-30","conditions":"Kidney Transplantation Recipients, Proteinuria Patients","enrollment":54},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT06562582","phase":"PHASE4","title":"STunning in Acute Myocardial Infarction - BAS","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2025-01-06","conditions":"Myocardial Infarct","enrollment":120},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT06226896","phase":"","title":"Effects of Dapagliflozin on Progression of Alport Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2023-11-15","conditions":"Alport Syndrome","enrollment":222},{"nctId":"NCT06532682","phase":"PHASE4","title":"Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-01","conditions":"Diabetic Kidney Disease, Type 1 Diabetes","enrollment":54},{"nctId":"NCT04707261","phase":"PHASE4","title":"Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","status":"RECRUITING","sponsor":"Xiangtan Central Hospital","startDate":"2021-08-06","conditions":"Anemia, Heart Failure","enrollment":1990},{"nctId":"NCT06201000","phase":"","title":"Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2023-12-27","conditions":"Genetic Polymorphisms, Heart Failure","enrollment":282},{"nctId":"NCT06187493","phase":"NA","title":"Treatment of Patients With Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2024-01-01","conditions":"Diabetic Kidney Disease","enrollment":70},{"nctId":"NCT05966818","phase":"PHASE4","title":"Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-08-01","conditions":"Nephrotic Syndrome","enrollment":90},{"nctId":"NCT05045274","phase":"NA","title":"The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-12","conditions":"STEMI - ST Elevation Myocardial Infarction, Left Ventricular Systolic Dysfunction","enrollment":300},{"nctId":"NCT04531397","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-01-01","conditions":"Proteinuria, Chronic Kidney Diseases","enrollment":""},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT03794518","phase":"PHASE3","title":"Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2019-03","conditions":"Risk Reduction","enrollment":648}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treatment group"],"phase":"marketed","status":"active","brandName":"Dapagliflozin+ACEI treatment","genericName":"Dapagliflozin+ACEI treatment","companyName":"Children's Hospital of Fudan University","companyId":"children-s-hospital-of-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to reduce blood glucose, while an ACE inhibitor blocks angiotensin-converting enzyme to lower blood pressure and reduce proteinuria. Used for Type 2 diabetes mellitus with hypertension or chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}